Chapter 25 – Molecular Hematopathology

[1]  A. Tefferi,et al.  FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. , 2006, Leukemia research.

[2]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[3]  A. Tefferi,et al.  Atypical myeloproliferative disorders: diagnosis and management. , 2006, Mayo Clinic proceedings.

[4]  H. Bobby Gaspar,et al.  Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype , 2006, British journal of haematology.

[5]  P. Gaulard,et al.  Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas , 2006, Oncogene.

[6]  M. Tallman,et al.  T-cell non-Hodgkin lymphoma. , 2006, Blood.

[7]  J. Cayuela,et al.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.

[8]  H. Kantarjian,et al.  Mature T‐cell leukemias , 2005, Cancer.

[9]  G. Ahmann,et al.  Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.

[10]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[11]  R. Fonseca,et al.  Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Armstrong,et al.  Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Gascoyne,et al.  Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Fröhling,et al.  Genetics of myeloid malignancies: pathogenetic and clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Naoe,et al.  Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis , 2005, Leukemia.

[17]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[18]  K. Karube,et al.  Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances , 2005, Leukemia.

[19]  D. Steensma,et al.  Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. , 2005, Mayo Clinic proceedings.

[20]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[21]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[22]  S. Bicciato,et al.  Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma , 2005, Oncogene.

[23]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[24]  H. Kantarjian,et al.  Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. , 2005, Mayo Clinic proceedings.

[25]  J. Cook.  Paraffin Section Interphase Fluorescence In Situ Hybridization in the Diagnosis and Classification of Non-Hodgkin Lymphomas , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[26]  R. Siebert,et al.  Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites , 2004, Leukemia.

[27]  Y. Pekarsky,et al.  Tcl1 as a model for lymphomagenesis. , 2004, Hematology/oncology clinics of North America.

[28]  S. Faderl,et al.  Monitoring of minimal residual disease in chronic myeloid leukemia. , 2004, Hematology/oncology clinics of North America.

[29]  H. Müller-Hermelink,et al.  Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. , 2004, The American journal of pathology.

[30]  S. Swerdlow,et al.  Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). , 2004, Human pathology.

[31]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[32]  J. Abgrall,et al.  Cytogenetic Studies in T-Cell Acute Lymphoblastic Leukemia (1981 – 2002) , 2004, Leukemia & lymphoma.

[33]  P. Gaulard,et al.  Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients , 2003 .

[34]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[35]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[36]  W. Hiddemann,et al.  AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. , 2003, Blood.

[37]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Sallan,et al.  Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment , 2003, Current opinion in hematology.

[39]  M. Kadin,et al.  Systemic and primary cutaneous anaplastic large cell lymphomas. , 2003, Seminars in hematology.

[40]  C. Meijer,et al.  ALK‐negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects–a review , 2003, The Journal of pathology.

[41]  J. O'fallon,et al.  Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia , 2003, British journal of haematology.

[42]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[43]  E. Haralambieva,et al.  Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. , 2003, Blood.

[44]  R. Bataille,et al.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[45]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[46]  R. Fonseca,et al.  Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. , 2002, Blood.

[47]  A. Rosenwald,et al.  Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. , 2002, Blood.

[48]  P. Gaulard,et al.  Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T‐cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression , 2002, Genes, chromosomes & cancer.

[49]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[50]  M. Du,et al.  Mucosa-associated lymphoid tissue lymphoma , 2002, Current opinion in hematology.

[51]  M. Urioste,et al.  Chromosomal changes pattern and gene amplification in T cell non-Hodgkin's lymphomas , 2001, Leukemia.

[52]  L. Beppu,et al.  The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. , 2001, Blood.

[53]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[54]  C. Craddock,et al.  Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. , 2001, Blood.

[55]  D. Gilliland,et al.  Molecular genetics of acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[56]  C. Harrison,et al.  The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. , 2001, Blood reviews.

[57]  I. Buño,et al.  Diagnostic utility of fluorescence in situ hybridization in mantle‐cell lymphoma , 2000, British journal of haematology.

[58]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[59]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[60]  N. Rouas-Freiss,et al.  molecule Beyond the increasing complexity of the immunomodulatory HLA-G , 2008 .

[61]  L. Medeiros,et al.  Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis , 2006, Modern Pathology.

[62]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.